

Estimated arterial stiffness and cardiovascular risk in chronic kidney disease – a study protocol

Marija Domislović¹, Ivan Brzić², Danilo Radunović¹, Vladimir Prelević¹,
Bojan Jelaković^{1,3}

¹ Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb

² School of Medicine, University of Rijeka

³ School of Medicine, University of Zagreb

ABSTRACT:

Introduction The prevalence of chronic kidney disease (CKD) in the general population is 9.1%. Current guidelines recommend a cut-off GFR value of 60 mL/min/1.73 m² for diagnosis of CKD, without considering the physiological decline of GFR with aging, or the association with cardiovascular (CV), cerebrovascular or renal outcomes. There is also an increase in arterial stiffness with aging, which is estimated by pulse wave velocity (PWV). **Aim** The aim of this study is to show how the ePWV predicts CV incidents independently of SCORE chart and traditional risk factors. **Materials and Methods** This prospective observational study will include 2058 subjects from the Endemic nephropathy in Croatia – epidemiology, diagnosis and etiopathogenesis scientific research project. **Conclusion** This will be the first study that could show how the estimated arterial stiffness, independently of CKD contributes to overall CV, cerebrovascular and renal risk. We could also, based on the results, propose an age-independent definition of CKD based on the association with CV disease and mortality.

KEYWORDS: chronic kidney disease, ePWV, cardiovascular risk, arterial stiffness

SAŽETAK:

PROCIJENJENA ARTERIJSKA KRUTOST I KARDIOVASKULARNI RIZIK U KRONIČNOJ BUBREŽNOJ BOLESTI – PROTOKOL STUDIJE

Uvod Učestalost kronične bubrežne bolesti (KBB) u općoj populaciji iznosi 9,1%. Današnje smjernice za dijagnozu preporučuju graničnu vrijednost glomerularne filtracije (GFR) od 60 mL/min/1,73m², ne uzimajući u obzir fiziološki pad GFR sa starenjem niti povezanost s kardiovaskularnim (KV), cerebrovaskularnim (CV) ili renalnim ishodom. Sa starenjem dolazi i do porasta krutosti velikih krvnih žila, koja se procjenjuje brzinom pulsno vala (ePWV). **Cilj rada** Cilj ovoga rada je pokazati kako ePWV predviđa KV incidente neovisno o procjeni KV rizika uporabom tablica SCORE i tradicionalnih čimbenika rizika. **Materijali i metode** Ovo prospektivno opservacijsko istraživanje uključit će 2058 ispitanika znanstveno-istraživačkoga projekta Endemska nefropatija u Hrvatskoj – epidemiologija, dijagnostika i etiopatogeneza. **Zaključak** Ovo će biti prva studija koja bi mogla pokazati kako procijenjena krutost velikih krvnih žila neovisno o KBB doprinosi ukupnom KV, CV i renalnom riziku. Također bismo na temelju rezultata mogli predložiti o dobi neovisnu definiciju KBB na temelju povezanosti s KV pobolom i smrtnosti.

KLJUČNE RIJEČI: kronična bubrežna bolest, ePWV, kardiovaskularni rizik, krutost velikih krvnih žila

OPEN ACCESS

Correspondence:

Marija Domislović
domislovic.marija@gmail.com

This article was submitted to RAD
CASA - Medical Sciences
as the original article

Conflict of Interest Statement:

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 25 October 2022

Accepted: 13 December 2022

Published: 21 December 2022

Citation:

Domislović M, Brzić I, Radunović D, Prelević V, Jelaković B. Estimated arterial stiffness and cardiovascular risk in chronic kidney disease – a study protocol. RAD CASA - Medical Sciences. 553=60-61 (2022): 34-38
DOI: 10.21857/yvjrdcvx1y

Copyright (C) 2022 Domislović M, Brzić I, Radunović D, Prelević V, Jelaković B. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

DETERMINATION OF CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR RISK

According to the results of the epidemiological studies, the prevalence of chronic kidney disease (CKD) in 2017 in the general population is 9.1% with an observed increase trend of 29.3% in the period from year 1990 to 2017 (1). High mortality from CKD was recorded in 2017 when the total number of deaths was more than 1 million, while CKD as the leading cause of death in the period from year 1990 to 2017 went from 12th to 17th place (1, 2). The most important factors that lead to an increase in prevalence of CKD are diabetes, arterial hypertension, and obesity (3,4,5). CKD is associated not only with the risk of end-stage renal disease and the need for replacement therapy, but already in the early stages it is an independent factor of cardiovascular (CV) risk. Research have shown that only one in five patients with CKD experience the need for replacement therapy, while the rest die most often due to CV or cerebrovascular causes (4,5,6). The presence of CKD, whether manifested as proteinuria, i.e. albuminuria or a decrease in glomerular filtration rate (GFR), is an independent risk factor for fatal and non-fatal CV outcomes (7,8). CV risk in CKD increases with decreasing estimated GFR (eGFR) value, from a 43% higher CV risk with eGFR values of 45 to 59 mL/min/1.73 m² to a 343% increase in CV risk with an eGFR value of less than 15 mL/min/1.73 m² (6). According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for the assessment and treatment of chronic kidney disease from 2012, the diagnosis of CKD is defined as a proven impairment of kidney function lasting longer than 3 months with a decrease in eGFR <60 mL/min/1.73 m² or without it and/or with the presence of albuminuria defined as the ratio of albumin to creatinine in the urine (English albumin creatinine ratio, ACR) >30 mg/g (7). The KDIGO 2012 guidelines recommend the use of the 2009 CKD Epi equation for determining eGFR in the adult population and alternative equations if they show greater precision compared to the CKD Epi equation (7,9). And according to the KDIGO guidelines for the treatment of glomerular diseases from 2021, the determination of creatinine clearance and the determination of glomerular filtration with cystatin and the use of the MDRD equation are recommended in the case when the value of glomerular filtration is less than 60 mL/min (10). The disadvantages of the CKD Epi equation are: 1. it is adjusted according to the unique value of the average body surface area (BSA), which is 1.73 m², which is significantly different from today's actual BSA value; 2. study in which the equation was derived included a small percentage of subjects over 70 years of age (9). There are debates about the proper definition of CKD and the threshold value of GFR for establishing the diagnosis of CKD (11-16). Today's guidelines recommend the use of an eGFR cut-off value of 60 mL/min/1.73 m², considering neither the physiological decline of GFR with aging nor the association with CV, cerebrovascular or

renal outcomes (16). Today, an age-adjusted definition of CKD has been proposed, where eGFR threshold values are different for those younger than 40 and older than 65 and are determined according to CV risk (16). This way of determining eGFR could distinguish physiological changes in GFR with age from those associated with actual CKD.

ESTIMATED ARTERIAL STIFFNESS AND CARDIOVASCULAR RISK

In addition to the fact that with aging there is a decrease in GFR, there is also an increase in the arterial stiffness. The increase in arterial stiffness with aging is a consequence of several pathophysiological mechanisms that lead to damage of the function of the vascular system. With aging, there are structural changes in the arteries, i.e. the degeneration of elastin fibres and their replacement by collagen that is much less elastic, and an increase in the production of vasoconstrictors with a decrease in the bioavailability of endothelial relaxation factors such as nitric oxide (NO) (17). In patients with CKD and end-stage kidney disease (ESKD), hyperphosphatemia, hypercalcemia and the development of secondary hyperparathyroidism also contribute to the increase in arterial stiffness (18). The increased concentration of serum phosphates plays a significant role in the formation of calcifications i.e., it leads to reduced arterial elasticity, and consequently increased arterial stiffness and higher CV mortality (19,20). Arterial stiffness, which is assessed by pulse wave velocity (PWV), is a strong predictor of CV incidents and mortality in the general population, in patients with arterial hypertension and especially in patients with CKD (21-23). According to the guidelines of the European Society of Cardiology from 2018, a PWV value >10 m/s is considered a pathological value that has a predictive value for CV incidents in hypertensive patients (24-27). Today, PWV can be reliably measured by different methods, such as tonometric, sonographic, oscillometric, piezoelectric methods or by implementation in existing devices for 24-hour continuous measurement of arterial pressure (28). The gold standard for determining PWV is the measurement of PWV from carotid to femoral artery (cfPWV). However, direct measurements of cfPWV have proven to be impractical in daily clinical work and in epidemiological studies. Recently, it has been shown that estimated PWV (ePWV) calculated by a validated equation that includes age and mean arterial pressure correlates well with cfPWV and has a predictive role in hypertensive patients with different degrees of CV risk (29). ePWV predicts CV events independently of CV risk assessment using SCORE tables and traditional risk factors defined according to the Framingham study (30-33). Studies have shown that ePWV should be used in daily clinical practice due to its simplicity of execution and high predictive value in CV risk assessment (27,32,33).




Figure 1. Study flowchart

Although it is known that CKD is an independent factor of CV risk, it is an open question how much does ePWV contributes to CV, cerebrovascular and renal risk in CKD that is defined with an age-adjusted definition.

STUDY AIMS

The aim of this study is to determine whether the predictivity of estimated arterial stiffness (ePWV) for fatal and nonfatal CV, cerebrovascular, and renal outcomes is independent of guideline-defined chronic kidney disease (CKD) that is defined as eGFR <60 mL/min/1.73 m² or age-adjusted definition of CKD. Also, this study will analyse risk factors for ePWV depending on the stage of CKD determined according to the guidelines and using an age-adjusted definition of CKD. We will show predictability of all traditional CV risk factors and ePWV for total and CV mortality, and for certain fatal and non-fatal outcomes and analyse causes of death and frequency of morbidity depending on ePWV in subjects classified as persons with CKD defined in both ways, and in persons without CKD.

STUDY DESIGN AND SUBJECTS

This will be a prospective, observational study that will include 2,058 adults, subjects of the scientific research project Endemic nephropathy in Croatia - epidemiology, diagnostics and etiopathogenesis (Ministry of Science, Education and Sports 108-000000329).

Subjects will be monitored for an average of 12 years (2005-2021). At the initial follow-up point, all subjects signed a written informed consent and filled out an extensive questionnaire containing information on personal and family history and were clinically examined, and blood and first urine sample was taken. In final follow-up point we will obtain the data on fatal and non-fatal CV, cerebrovascular and renal outcomes from the archives of general practitioners and from the register of deaths of the Croatian Institute of Public Health. Causes of fatal and non-fatal outcomes will be classified using International Classification of Diseases (ICD 10) codes. We will calculate ePWV values using the validated equation: $ePWV = 9.587 - 0.402 \times \text{age} + 4.560 \times 10^{-3} \times \text{age}^2 - 2.621 \times 10^{-5} \times \text{age}^2 \times \text{mean arterial pressure (MBP)} + 3.176 \times 10^{-3} \times \text{age} \times \text{MBP} - 1.832 \times 10^{-2} \times \text{MBP}$ (29). The total risk will be calculated using accepted risk sums (Heart Score and Framingham risk score).

SCIENTIFIC CONTRIBUTION

The expected scientific contribution of this study is that, based on the obtained results, the contribution of the ePWV, independent of CKD, to the total CV, cerebrovascular and renal risk could be confirmed, which was not done in previous studies. Secondly, our results would contribute to the introduction of an age-adjusted definition of CKD in clinical practice.

REFERENCES:

1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global burden of disease study 2017. *Lancet*. 2020;395(10225):709-33.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global burden of disease study 2017. *Lancet*. 2018;392(10159):1789-858.
3. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of world-wide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int*. 2015;88:950-7.
4. Tonelli M, Pfeffer M. Kidney disease and cardiovascular risk. *Annu Rev Med*. 2007;58:123-39.
5. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet*. 2013;382:339-52.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351:1296-305.
7. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med*. 2013;158(11):825-30.
8. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. *Hypertension*. 2003;42(5):1050-65.
9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604-12.
10. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. *Kidney Int*. 2021;100(4):753-79.
11. Levin A, Stevens P. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. *Kidney Int*. 2013;85:49-61.
12. O'Hare AM, Bertenthal D, Covinsky KE, Landefeld CS, Sen S, Mehta K, et al. Mortality risk stratification in chronic kidney disease: one size for all ages? *J Am Soc Nephrol*. 2006;17:846-53.
13. O'Hare AM. Measures to define chronic kidney disease. *JAMA*. 2013;309:1343-4.
14. Wetzels J, Kiemeneij L, Swinkels D, Willems H, den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen biomedical study. *Kidney Int*. 2007;72:632-7.
15. De Broe M, Gharbi M, Zamd M, Elseviers M. Why overestimate or underestimate chronic kidney disease when correct estimation is possible. *Nephrol Dial Transplant*. 2017;32:ii136-41.
16. Delanaye P, Glassock R, Pottel H, Rule AD. An age-calibrated definition of chronic kidney disease: rationale and benefits. *Clin Biochem Rev*. 2016;37:17-26.
17. Tsai JP, Hsu BG. Arterial stiffness: a brief review. *Tzu Chi Med J*. 2020;33(2):115-21.
18. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. *J Am Soc Nephrol*. 2008;19(9):1827-35.
19. Shroff R. Phosphate is a vascular toxin. *Pediatr Nephrol*. 2013;28(4):583-93.
20. Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought. *Cardiovasc Pathol*. 2012;21(5):372-81.
21. Vlachopoulos C, Terentes-Printzios D, Laurent S, Nilsson PM, Protogerou AD, Aznaouridis K, et al. Association of estimated pulse wave velocity with survival: a secondary analysis of SPRINT. *JAMA Netw Open*. 2019;2(10):e1912831.
22. Suzuki H, Inoue T, Dogi M, Kikuta T, Takenaka T, Okada H. Role of pulse wave velocity in patients with chronic kidney disease stages 3-5 on long-term follow-up. *Pulse (Basel)*. 2014;2(1-4):1-10.
23. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010;55(13):1318-27.
24. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. *J Hypertens*. 2018;36(10):1953-2041.
25. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012;30:445-8.

26. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol*. 2014;63(7):636-46.
27. Ji C, Gao J, Huang Z, Chen S, Wang G, Wu S, et al. Estimated pulse wave velocity and cardiovascular events in Chinese. *Int J Cardiol Hypertens*. 2020;7:100063.
28. Lioufas N, Hawley CM, Cameron JD, Toussaint ND. Chronic kidney disease and pulse wave velocity: a narrative review. *Int J Hypertens*. 2019;2019:9189362.
29. Greve SV, Blicher MK, Kruger R, Sehestedt T, Gram-Kampmann E, Rasmussen S, et al. Estimated carotid-femoral pulse wave velocity has similar predictive value as measured carotid-femoral pulse wave velocity. *J Hypertens*. 2016;34(7):1279-89.
30. Vishram-Nielsen JKK, Laurent S, Nilsson PM, Linneberg A, Sehested TSG, Greve SV, et al. Does estimated pulse wave velocity add prognostic information?: MORGAM prospective cohort project. *Hypertension*. 2020;75(6):1420-8.
31. Heffernan KS, Jae SY, Loprinzi PD. Estimated pulse wave velocity is associated with residual-specific mortality: findings from the National health and nutrition examination survey. *J Hypertens*. 2021;39(4):698-702.
32. Jae SY, Heffernan KS, Kurl S, Kunutsor SK, Laukkanen JA. Association between estimated pulse wave velocity and the risk of stroke in middle-aged men. *Int J Stroke*. 2021;16(5):551-5.
33. Hsu PC, Lee WH, Tsai WC, Chen YC, Chu CY, Yen HW, et al. Comparison between estimated and brachial-ankle pulse wave velocity for cardiovascular and overall mortality prediction. *J Clin Hypertens (Greenwich)*. 2021;23(1):106-13.

